Market Research Logo

Enzyme Replacement Therapy Market: Injectable Expected to be the Most Preferred Route of Administration: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

Enzyme Replacement Therapy Market: Injectable Expected to be the Most Preferred Route of Administration: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

This Future Market Insights report examines the ‘Enzyme Replacement Therapy Market’ for the period 2013–2017 and provides forecasts for 2018–2028. The primary objective of the report is to offer updates and in-depth analysis of the global market opportunities for Enzyme Replacement Therapy (ERT).

Increase in the global demand for ERT for the treatment of rare diseases is anticipated to drive the market over the forecast period. Increase in government spending on healthcare infrastructure such as favourable reimbursement for ERT is expected to boost the global market. Growth in the number of research initiatives with the help of non-profit organisations and increase in government support are also among factors expected to fuel market growth.

However, the availability of alternative treatment options and high treatment cost are some of the factors that are expected to hamper the growth of the global market. Dearth of skilled healthcare professionals and lack of regulatory framework in emerging economics are also likely to restrain the global market over the forecast period.

The global enzyme replacement therapy market has been segmented on the basis of:

Therapeutic Conditions

Route of Administration

Distribution Channels

Regions

The report analyses the global ERT market in terms of value (US$ Mn). The report begins with the definition of the market and explains different therapeutic conditions. The market viewpoint section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro factors that influence the global market. Opportunity analysis provided in this section equips clients with crystal clear decision-making insights.

The report analyses the market based on regions and presents the forecast in terms of value for the next 10 years. Regions covered in the report include:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific excluding China & Japan (APECJ)

China

Japan

Middle East & Africa (MEA)

Each of these sections analyse regional markets by therapeutic condition, route of administration, distribution channels and country. The regional market dynamics section provides key growth trends pertaining to each region. The representative market participants section consists of a list of companies that operate in different regions, competitive landscape and intensity map of their presence in each region.

Weighted average selling price is considered to estimate the market size of various devices mentioned in the scope of the study. The country price is captured with the local currency. The local currency figures are converted into USD to offer forecasts in a consistent currency standard. Furthermore, FMI also considers the latest annual exchange rate to reflect the impact of the most recent economic conditions of country. Prices considered in these models are standardised based on the average cost per ERT.

The forecast presented in the report provides total revenue of approved ERT over 2018–2028. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

In the next section of the report, a ‘Competitive Landscape’ is included to provide a dashboard view and to access the key differentiators among competitor firms. This section is primarily designed to provide clients an objective and detailed comparative assessment of product offerings and strategies of key providers specific to market segments. Detailed profiles of market players are also provided in the report, which highlight company description, overview, product/segment overview, SWOT analysis, financial information, key developments related to the market and strategic overview.

The next section of report analyses the market based on therapeutic conditions and presents the forecast in terms of value for the next 10 years. Therapeutic conditions covered in the report include:

Fabry Disease

Gaucher Disease

Mucopolysaccharidosis

MPS I

MPS II (Hunter syndrome)

MPS IVA (Morquio syndrome, type A)

MPS VI (Maroteaux-Lamy syndrome)

MPS VII (Sly syndrome)

Pompe Disease

Lysosomal Acid Lipase Deficiency

Others

The next section of report analyses the market based on the route of administration of ERT and provides forecast in terms of value for the next 10 years. On the basis of route of administration, the market is segmented into:

Oral

Injectable

The next section of report analyses the market based on the distribution channels of ERT and provides forecast in terms of value for the next 10 years. On the basis of distribution channel, the market is segmented into:

Hospital Pharmacies

Specialty Treatment Pharmacies

Retail Pharmacies

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve as well as to identify potential resources from a sales and delivery perspective of products. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis that helps clients identify real market opportunities.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Enzyme Replacement Therapy Market View Point Analysis
3.1. Macro-Economic Factors
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Trends
3.3. Opportunity Analysis
3.4. Value Chain Analysis
4. Macroeconomic Assumptions
5. Global Economic Outlook
5.1. Gross Domestic Product by Region & Country, 2006 – 2021
5.2. Global Pharmaceutical Market Outlook
6. Key Inclusions
6.1. Rare Disease Framework
6.2. Orphan Drug Key Regulations, By Country
6.3. Pipeline Assessment of Enzyme Replacement Therapy
7. North America Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Trends
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
7.3.1. U.S.
7.3.2. Canada
7.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
7.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
7.5.1. Fabry Disease
7.5.2. Gaucher Disease
7.5.3. Mucopolysaccharidosis
7.5.3.1. MPS I
7.5.3.2. MPS II (Hunter syndrome)
7.5.3.3. MPS IVA (Morquio syndrome, type A)
7.5.3.4. MPS VI (Maroteaux-Lamy syndrome)
7.5.3.5. MPS VII (Sly syndrome)
7.5.4. Pompe Disease
7.5.5. Lysosomal acid lipase Deficiency
7.5.6. Others
7.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
7.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
7.7.1. Oral
7.7.2. Injectable
7.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
7.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
7.9.1. Hospital Pharmacies
7.9.2. Specialty Treatment Pharmacies
7.9.3. Retail Pharmacies
7.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
7.11. Market Attractiveness Analysis
7.11.1. By Country
7.11.2. By Therapeutic Condition
7.11.3. By Route of Administration
7.11.4. By Distribution Channel
7.12. Drivers and Restraints: Impact Analysis
7.13. Key Market Participants – Intensity Mapping
8. Latin America Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
8.3.1. Brazil
8.3.2. Mexico
8.3.3. Rest of Latin America
8.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
8.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
8.5.1. Fabry Disease
8.5.2. Gaucher Disease
8.5.3. Mucopolysaccharidosis
8.5.3.1. MPS I
8.5.3.2. MPS II (Hunter syndrome)
8.5.3.3. MPS IVA (Morquio syndrome, type A)
8.5.3.4. MPS VI (Maroteaux-Lamy syndrome)
8.5.3.5. MPS VII (Sly syndrome)
8.5.4. Pompe Disease
8.5.5. Lysosomal acid lipase Deficiency
8.5.6. Others
8.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
8.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
8.7.1. Oral
8.7.2. Injectable
8.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
8.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
8.9.1. Hospital Pharmacies
8.9.2. Specialty Treatment Pharmacies
8.9.3. Retail Pharmacies
8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Therapeutic Condition
8.11.3. By Route of Administration
8.11.4. By Distribution Channel
8.12. Drivers and Restraints: Impact Analysis
8.13. Key Market Participants – Intensity Mapping
9. Western Europe Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Trends
9.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
9.3.1. Germany
9.3.2. U.K
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Western Europe
9.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
9.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
9.5.1. Fabry Disease
9.5.2. Gaucher Disease
9.5.3. Mucopolysaccharidosis
9.5.3.1. MPS I
9.5.3.2. MPS II (Hunter syndrome)
9.5.3.3. MPS IVA (Morquio syndrome, type A)
9.5.3.4. MPS VI (Maroteaux-Lamy syndrome)
9.5.3.5. MPS VII (Sly syndrome)
9.5.4. Pompe Disease
9.5.5. Lysosomal acid lipase Deficiency
9.5.6. Others
9.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
9.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
9.7.1. Oral
9.7.2. Injectable
9.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
9.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
9.9.1. Hospital Pharmacies
9.9.2. Specialty Treatment Pharmacies
9.9.3. Retail Pharmacies
9.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
9.11. Market Attractiveness Analysis
9.11.1. By Country
9.11.2. By Therapeutic Condition
9.11.3. By Route of Administration
9.11.4. By Distribution Channel
9.12. Drivers and Restraints: Impact Analysis
9.13. Key Market Participants – Intensity Mapping
10. Eastern Europe Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
10.3.1. Russia
10.3.2. Poland
10.3.3. Rest of Eastern Europe
10.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
10.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
10.5.1. Fabry Disease
10.5.2. Gaucher Disease
10.5.3. Mucopolysaccharidosis
10.5.3.1. MPS I
10.5.3.2. MPS II (Hunter syndrome)
10.5.3.3. MPS IVA (Morquio syndrome, type A)
10.5.3.4. MPS VI (Maroteaux-Lamy syndrome)
10.5.3.5. MPS VII (Sly syndrome)
10.5.4. Pompe Disease
10.5.5. Lysosomal acid lipase Deficiency
10.5.6. Others
10.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
10.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
10.7.1. Oral
10.7.2. Injectable
10.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
10.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
10.9.1. Hospital Pharmacies
10.9.2. Specialty Treatment Pharmacies
10.9.3. Retail Pharmacies
10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
10.11. Market Attractiveness Analysis
10.11.1. By Country
10.11.2. By Therapeutic Condition
10.11.3. By Route of Administration
10.11.4. By Distribution Channel
10.12. Drivers and Restraints: Impact Analysis
10.13. Key Market Participants – Intensity Mapping
11. Asia Pacific Excluding China & Japan Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
11.1. Introduction
11.2. Regional Market Trends
11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
11.3.1. India
11.3.2. Australia and New Zealand
11.3.3. ASEAN
11.3.4. Rest of APECJ
11.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
11.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
11.5.1. Fabry Disease
11.5.2. Gaucher Disease
11.5.3. Mucopolysaccharidosis
11.5.3.1. MPS I
11.5.3.2. MPS II (Hunter syndrome)
11.5.3.3. MPS IVA (Morquio syndrome, type A)
11.5.3.4. MPS VI (Maroteaux-Lamy syndrome)
11.5.3.5. MPS VII (Sly syndrome)
11.5.4. Pompe Disease
11.5.5. Lysosomal acid lipase Deficiency
11.5.6. Others
11.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
11.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
11.7.1. Oral
11.7.2. Injectable
11.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
11.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
11.9.1. Hospital Pharmacies
11.9.2. Specialty Treatment Pharmacies
11.9.3. Retail Pharmacies
11.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
11.11. Market Attractiveness Analysis
11.11.1. By Country
11.11.2. By Therapeutic Condition
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.12. Drivers and Restraints: Impact Analysis
11.13. Key Market Participants – Intensity Mapping
12. China Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
12.2.1. Fabry Disease
12.2.2. Gaucher Disease
12.2.3. Mucopolysaccharidosis
12.2.3.1. MPS I
12.2.3.2. MPS II (Hunter syndrome)
12.2.3.3. MPS IVA (Morquio syndrome, type A)
12.2.3.4. MPS VI (Maroteaux-Lamy syndrome)
12.2.3.5. MPS VII (Sly syndrome)
12.2.4. Pompe Disease
12.2.5. Lysosomal acid lipase Deficiency
12.2.6. Others
12.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
12.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
12.4.1. Oral
12.4.2. Injectable
12.5. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
12.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
12.6.1. Hospital Pharmacies
12.6.2. Specialty Treatment Pharmacies
12.6.3. Retail Pharmacies
12.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
12.8. Market Attractiveness Analysis
12.8.1. By Therapeutic Condition
12.8.2. By Route of Administration
12.8.3. By Distribution Channel
12.9. Drivers and Restraints: Impact Analysis
12.10. Key Market Participants – Intensity Mapping
13. Japan Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
13.2.1. Fabry Disease
13.2.2. Gaucher Disease
13.2.3. Mucopolysaccharidosis
13.2.3.1. MPS I
13.2.3.2. MPS II (Hunter syndrome)
13.2.3.3. MPS IVA (Morquio syndrome, type A)
13.2.3.4. MPS VI (Maroteaux-Lamy syndrome)
13.2.3.5. MPS VII (Sly syndrome)
13.2.4. Pompe Disease
13.2.5. Lysosomal acid lipase Deficiency
13.2.6. Others
13.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
13.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
13.4.1. Oral
13.4.2. Injectable
13.5. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
13.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
13.6.1. Hospital Pharmacies
13.6.2. Specialty Treatment Pharmacies
13.6.3. Retail Pharmacies
13.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
13.8. Market Attractiveness Analysis
13.8.1. By Therapeutic Condition
13.8.2. By Route of Administration
13.8.3. By Distribution Channel
13.9. Drivers and Restraints: Impact Analysis
13.10. Key Market Participants – Intensity Mapping
14. Middle East and Africa Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
14.1. Introduction
14.2. Regional Market Trends
14.3. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market Size (US$ Mn) Forecast By Country, 2018-2028
14.5. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Condition, 2013-2017
14.5.1. Fabry Disease
14.5.2. Gaucher Disease
14.5.3. Mucopolysaccharidosis
14.5.3.1. MPS I
14.5.3.2. MPS II (Hunter syndrome)
14.5.3.3. MPS IVA (Morquio syndrome, type A)
14.5.3.4. MPS VI (Maroteaux-Lamy syndrome)
14.5.3.5. MPS VII (Sly syndrome)
14.5.4. Pompe Disease
14.5.5. Lysosomal acid lipase Deficiency
14.5.6. Others
14.6. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
14.7. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017
14.7.1. Oral
14.7.2. Injectable
14.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
14.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
14.9.1. Hospital Pharmacies
14.9.2. Specialty Treatment Pharmacies
14.9.3. Retail Pharmacies
14.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
14.11. Market Attractiveness Analysis
14.11.1. By Country
14.11.2. By Therapeutic Condition
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.12. Drivers and Restraints: Impact Analysis
14.13. Key Market Participants – Intensity Mapping
15. Forecast Factors: Relevance and Impact
16. Market Structure Analysis
16.1. Market Structure by Tier
16.2. Market Share Analysis (2017) for Top 10 Players, By Region
17. Competition Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Profitability and Gross Margin Analysis By Competition
17.4. Competitors Deep Dive
17.4.1. Sanofi S.A. (Genzyme Corporation)
17.4.1.1. Overview
17.4.1.2. Product and Application Portfolio
17.4.1.3. Production Footprint
17.4.1.4. Sales Footprint
17.4.1.5. Channel Footprint
17.4.1.6. Strategy
17.4.1.6.1. Marketing Strategy
17.4.1.6.2. Product Strategy
17.4.1.6.3. Channel Strategy
17.4.2. Shire plc.
17.4.2.1. Overview
17.4.2.2. Product and Application Portfolio
17.4.2.3. Production Footprint
17.4.2.4. Sales Footprint
17.4.2.5. Channel Footprint
17.4.2.6. Strategy
17.4.2.6.1. Marketing Strategy
17.4.2.6.2. Product Strategy
17.4.2.6.3. Channel Strategy
17.4.3. Pfizer Inc.
17.4.3.1. Overview
17.4.3.2. Product and Application Portfolio
17.4.3.3. Production Footprint
17.4.3.4. Sales Footprint
17.4.3.5. Channel Footprint
17.4.3.6. Strategy
17.4.3.6.1. Marketing Strategy
17.4.3.6.2. Product Strategy
17.4.3.6.3. Channel Strategy
17.4.4. Alexion Pharmaceuticals, Inc.
17.4.4.1. Overview
17.4.4.2. Product and Application Portfolio
17.4.4.3. Production Footprint
17.4.4.4. Sales Footprint
17.4.4.5. Channel Footprint
17.4.4.6. Strategy
17.4.4.6.1. Marketing Strategy
17.4.4.6.2. Product Strategy
17.4.4.6.3. Channel Strategy
17.4.5. BioMarin Pharmaceutical Inc.
17.4.5.1. Overview
17.4.5.2. Product and Application Portfolio
17.4.5.3. Production Footprint
17.4.5.4. Sales Footprint
17.4.5.5. Channel Footprint
17.4.5.6. Strategy
17.4.5.6.1. Marketing Strategy
17.4.5.6.2. Product Strategy
17.4.5.6.3. Channel Strategy
17.4.6. Ultragenyx Pharmaceutical Inc.
17.4.6.1. Overview
17.4.6.2. Product and Application Portfolio
17.4.6.3. Production Footprint
17.4.6.4. Sales Footprint
17.4.6.5. Channel Footprint
17.4.6.6. Strategy
17.4.6.6.1. Marketing Strategy
17.4.6.6.2. Product Strategy
17.4.6.6.3. Channel Strategy
17.4.7. Johnson & Johnson Services, Inc.
17.4.7.1. Overview
17.4.7.2. Product and Application Portfolio
17.4.7.3. Production Footprint
17.4.7.4. Sales Footprint
17.4.7.5. Channel Footprint
17.4.7.6. Strategy
17.4.7.6.1. Marketing Strategy
17.4.7.6.2. Product Strategy
17.4.7.6.3. Channel Strategy
17.4.8. Allergan plc.
17.4.8.1. Overview
17.4.8.2. Product and Application Portfolio
17.4.8.3. Production Footprint
17.4.8.4. Sales Footprint
17.4.8.5. Channel Footprint
17.4.8.6. Strategy
17.4.8.6.1. Marketing Strategy
17.4.8.6.2. Product Strategy
17.4.8.6.3. Channel Strategy
17.4.9. Leadiant Biosciences, Inc.
17.4.9.1. Overview
17.4.9.2. Product and Application Portfolio
17.4.9.3. Production Footprint
17.4.9.4. Sales Footprint
17.4.9.5. Channel Footprint
17.4.9.6. Strategy
17.4.9.6.1. Marketing Strategy
17.4.9.6.2. Product Strategy
17.4.9.6.3. Channel Strategy
18. Global Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027 By Region
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Mn) Analysis By Region
18.2.1. North America
18.2.2. Latin America
18.2.3. Western Europe
18.2.4. Eastern Europe
18.2.5. Asia Pacific Excluding Japan And China
18.2.6. China
18.2.7. Japan
18.2.8. Middle East and Africa
18.3. Market Size (US$ Mn) Forecast By Region
18.4. Market Attractiveness Analysis By Region
19. Global Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Condition
19.1. Introduction/Key Finding
19.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Condition, 2013-2017
19.2.1. Fabry Disease
19.2.2. Gaucher Disease
19.2.3. Mucopolysaccharidosis
19.2.3.1. MPS I
19.2.3.2. MPS II (Hunter syndrome)
19.2.3.3. MPS IVA (Morquio syndrome, type A)
19.2.3.4. MPS VI (Maroteaux-Lamy syndrome)
19.2.3.5. MPS VII (Sly syndrome)
19.2.4. Pompe Disease
19.2.5. Lysosomal acid lipase Deficiency
19.2.6. Others
19.3. Market Size (US$ Mn) Forecast By Therapeutic Condition, 2018-2028
19.4. Market Attractiveness Analysis By Therapeutic Condition
20. Global Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027, By Route of Administration
20.1. Introduction/Key Finding
20.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2013-2017
20.2.1. Oral
20.2.2. Injectable
20.3. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028
20.4. Market Attractiveness Analysis By Route of Administration
21. Global Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel
21.1. Introduction/Key Finding
21.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2017
21.2.1. Hospital Pharmacies
21.2.2. Specialty Treatment Pharmacies
21.2.3. Retail Pharmacies
21.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2028
21.4. Market Attractiveness Analysis By Distribution Channel
22. Global Enzyme Replacement Therapy Market Analysis 2012–2016 and Forecast 2017–2027
22.1. Market Value Share Analysis By All Segment
22.2. Y-o-Y Growth Analysis By All Segment
22.3. Absolute $ Opportunity
23. Assumptions and Acronyms Used
24. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report